Journal of International Oncology ›› 2020, Vol. 47 ›› Issue (11): 695-699.doi: 10.3760/cma.j.cn371439-20200406-00103

• Reviews • Previous Articles     Next Articles

Heart protection in the treatment of breast cancer

Liu Guibin, Gao Jie, Ma Ying()   

  1. Department of Cardiology, Qingdao Municipal Hospital, Qingdao 266000, China
  • Received:2020-04-06 Revised:2020-08-21 Online:2020-11-08 Published:2021-01-05
  • Contact: Ma Ying E-mail:maying3211@163.com

Abstract:

Breast cancer patients have a higher risk of cardiovascular disease, older age, lower ejection fraction, history of coronary artery disease, cardiac risk factors, anthracycline combined with trastuzumab or radiotherapy will increase the risk of cardiac events after treatment. Echocardiographic monitoring the heart condition, especially for those patients with traditional heart risk factors such as hypertension, diabetes, hyperlipidemia and obesity or with low left ventricular ejection fraction at normal baseline, can reduce cardiac risk events. Elevated troponin and early myocardial deformation during anthracycline therapy may indicate a decrease in ejection fraction, but further studies are needed to prove the clinical benefits of routine screening and early treatment. For patients with breast cancer, smoking cessation,regular exercise, healthy diet and maintaining a healthy weight, etc., can reduce the risk of cardiovascular disease.

Key words: Breast neoplasms, Heart failure, Coronary artery disease, Hypertension